雲內動力(000903.SZ):控股股東混改項目已徵集到兩家意向投資方
格隆匯4月6日丨雲內動力(000903.SZ)公佈,2020年4月3日,公司收到控股股東雲內集團通知,雲內集團混改項目已徵集到意向投資方B一家,為雲南卓岑商貿有限公司。上述意向投資方已向北京產權交易所提交了申請資料且繳納了保證金。
截至2020年4月3日,雲內集團混改項目已徵集到意向投資方A一家,為全威(銅陵)銅業科技有限公司;徵集到意向投資方B一家,為雲南卓岑商貿有限公司。
根據雲內集團混改方案的要求,上述徵集到的意向投資方A和意向投資方B尚需經昆明市委、市政府審定,審定期間暫不接受其他意向投資方報名。若審定通過,此次混改項目掛牌結束;若審定未通過,此次混改項目掛牌繼續延期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.